Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information.
about
Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's DiseaseQualitative and quantitative assessment of self-reported cognitive difficulties in nondemented elders: Association with medical help seeking, cognitive deficits, and β-amyloid imaging.Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals.MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study
P2860
Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Assessing risk for preclinical ...... , and demographic information.
@en
Assessing risk for preclinical ...... , and demographic information.
@nl
type
label
Assessing risk for preclinical ...... , and demographic information.
@en
Assessing risk for preclinical ...... , and demographic information.
@nl
prefLabel
Assessing risk for preclinical ...... , and demographic information.
@en
Assessing risk for preclinical ...... , and demographic information.
@nl
P2093
P2860
P50
P1476
Assessing risk for preclinical ...... , and demographic information.
@en
P2093
Philip S Insel
R Scott Mackin
Rachel L Nosheny
Sebastian Palmqvist
P2860
P356
10.1016/J.DADM.2016.07.002
P577
2016-08-03T00:00:00Z